Who is a Class Member
The Zicam Cold Medicine class action settlement includes “all residents of the United States of America who purchased any of the following Zicam products in the United States from February 15, 2011 through June 5, 2018:
- RapidMelts Original
- RapidMelts Ultra
- Oral Mist
- Ultra Crystals
- Lozenges Ultra
- Soft Chews
- Medicated Fruit Drops; and
If you don’t qualify for this settlement, check out our database of other class action settlementsyou may be eligible for.
- $6.16-$11.53 per product purchased, up to 5 products (without proof of purchase)
Class members who submit a valid and timely claim can receive cash payment of up to five units of the Zicam products (without requiring proof of purchase). Claims based on purchases of six or more of the Products will require proof of purchase. Your payment will be adjusted based on the number of claims submitted, which may increase or decrease your payout.
Proof of Purchase
- With proof of purchase, you can receive the actual price you paid for six or more Zicam products. Proof of purchase includes receipts or invoices, packaging, bottles, containers, or other documentation reflecting your purchase. If you do not submit proof of purchase, you will receive the MSRP for those products.
Zicam Cold Medicine Settlement Notes
- Melgar v. Zicam LLC et al.
- Case No. 2:14-cv-00160-MCE-AC
- Pending in the U.S. District Court for the Eastern District of California
In February 2014 plaintiff Yesenia Melgar filed this class action lawsuit against Zicam LLC over allegations company falsely advertises the effectiveness of their over-the-counter cold medications. Specifically, the Zicam class action lawsuit contends that Zicam’s sales pitch that its products are “clinically proven to shorten cold”, “reduces teh durination and severity of the common cold” are bogus because Zicam products are nothing more than placebos.
According to the complaint, Zicam cold medicine products have highly diluted concentrations of its “so-called” active ingredients and have no pharmalogical effect. In fact, Melgar says that while she used the Zicam medicine as directed, she did not obtain the advertised relief from her cold symptoms. Rather, she became much sicker because she forewent other treatment, based on her belief that the Zicam cold medicine would reduce the duration of her cold.
Zicam denies the claims. Complete details about the case and settlement are provided on the Zicam cold medicine settlement website.
Class members who wish to object to or exclude themselves from the Zicam cold medicine settlement must do so by October 3, 2018. Class members who wish to participate in the settlement must submit a claim form on or before October 3, 2018.
- 10/3/18: Claim Form Deadline
- 10/3/18: Objection or Exclusion Deadline
- 11/15/18 Final Hearing at 2:00 pm PT* (class members do not need to attend this hearing in order to receive a slice of the settlement pie).
*Settlement Class Members who wish to speak at the hearing should check www.ZicamClassAction.com to confirm that the date or time of the Hearing has not been changed.
- Mail: Zicam Class Action, c/o RG/2 Claims Administration, P.O. Box 59479, Philadelphia, PA 19102-9479
- Phone: 1-855-279-8685
- Email: email@example.com
- L. Timothy Fisher of Bursor & Fisher PA